Hidradenitis Suppurativa Research priorities
The HS Trust has worked closely with the James Lind Alliance and the UK
Dermatology Clinical Trials Network in order to set up a Priority Setting
Partnership. 609 people responded to the initial survey, submitting
1,432 questions/statements for the PSP to review.
The Hidradenitis Suppurativa Priority Setting Partnership (HS PSP) has now
achieved its aim and identified the questions about Hidradenitis Suppurativa
(HS) that matter most to patients, carers and clinicians. The HS PSP Steering
Group are delighted to announce the top 10 research uncertainties.
TOP 10 Research Priorities:
What is the most effective and safe group of oral treatments in treating HS? (e.g. antibiotics, hormonal treatments, retinoids, immunosuppressants, metformin, steroids)
What is the best management of an acute flare?
What is the impact of HS and the treatments on people with HS (physical, psychological, financial, social, quality of life)
How effective are biologics (etanercept, adalimumab, infliximab, ustekinumab) in treating HS?
Does early diagnosis and aggressive treatment influence the course of HS?
What is the best surgical procedure to perform in treating HS e.g. incision & drainage, local excision, wide excision?
Which factors are useful in determining the prognosis (disease progression) of HS?
What is the best method of wound care after surgery or for active disease?(e.g. Skin grafts, secondary intention, dressings)
To what extent is HS caused by genetic factors?
What is the best management of pain associated with HS?
For more information about the PSP and the uncertainties identified in the research, please visit the James Lind Alliance website